Endocrine Abstracts

Introduction and Objective: Pheochromocytomas are usually monocomponent tumors, but very rarely there are also composite pheochromocytomas, with another medullary component (benign or malignant) derived from the neural crest present. Even more rarely there are mixed corticomedullary tumors, with pheochromocytoma plus a cortical adrenal tumor, eventually causing primary aldosteronism or hypercortisolim. Our objective in this communication is to illustrate an infrequent variety ...

Introduction and Objectives: Vitamin D deficiency is highly prevalent. Both physicians and the population are increasingly aware of this fact, and the demand for determinations of vitamin D has escalated. The vitamin D status of the patients is most commonly assessed by the measurement of 25-hydroxycholecalciferol using an automated immunoassay. However, immunoassays are prone to interferences by circulating immunoglobulins such as rheumatoid factor, or more rarely by paraprot...

Introduction and Objectives: Since 2005, the NICE guidelines on T2DM recommend extended-release metformin (XRM) in patients with gastrointestinal disturbances induced by conventional metformin, as the tolerance of XRM is clearly superior, improving patient compliance, satisfaction and outcomes. In Spain XRM is recently available, but only in a fixed combination with sitagliptin. As yet, data on the efficacy, tolerability and impact on lipid profile of this combination are not ...

Introduction and Objectives: Extended-release (ER) metformin may reduce the gastrointestinal adverse effects of conventional metformin, increasing compliance, adherence and persistence. In mid 2022, a single-pill combination (SPC) containing 50 mg sitagliptin plus 1000 mg ER metformin was released in Spain, while monocomponent ER metformin is still unavailable. We rechallenged patients with T2DM labelled as metformin-intolerant and treated with a DPP4i with the mentioned SPC i...

Introduction and Objectives: Proton-pump inhibitors (PPI) are some of the most commonly prescribed drugs, and they are generally well tolerated. However, their long-term use has been associated with adverse effects such as acute interstitial nephritis, Clostridium difficile infection. pneumonia, and (controversially) bone fractures, cardiovascular disease and dementia. The acidification of the intestinal milieu may interfere with TRMP6-mediated active absorption of magnesium i...

Introduction and Objective: Metformin is still a mainstay of treatment in patients with type 2 diabetes mellitus (T2DM), but in 10-25% of them there are persistent gastrointestinal disturbances that worsen their quality of life, lead to poor compliance and treatment withdrawal, and ultimately result in worse health outcomes. Extended-Release Metformin (XRM) is much better tolerated, and since 2005 is recommended in the well-respected British NICE guidelines for the treatment o...

Introduction and Objectives: The tolerance of extended-release metformin (XRM) is superior to that of conventional metformin. XRM is recently available in Spain as a fixed combination with sitagliptin, but not in monotherapy. There are no data yet on how additional antidiabetic treatment can modify the effects of the XRM/sitagliptin combination. After assessing the efficacy and tolerability of XRM/sitagliptin in patients with T2DM labelled as metformin-intolerant and treated w...

Introduction and Objectives: Extended-release metformin (XRM) is recently available in Spain as a fixed combination with sitagliptin, but not in monotherapy. Its tolerance is clearly superior to that of conventional metformin, and since 2005 the NICE guidelines for type 2 diabetes mellitus (T2DM) recommend its use in patients with metformin-caused gastrointestinal disturbances. We assessed the efficacy and tolerability of XRM/sitagliptin in patients with T2DM previously labell...

Introduction and Objectives: The prevalence of prediabetes in the adult Spanish population is close to 15%. People with prediabetes are not only at high risk of developing T2DM but also at high cardiovascular risk. Several drugs, including metformin, glitazones, GLP-1RAs and SGLT2is have been found to reduce the incidence of diabetes in this population, but none is currently licensed with this indication. In particular α-glucosidase inhibitors such as acarbose have been s...

Introduction and Objective: Extended-release metformin has much better gastrointestinal tolerability than conventional (immediate release)metformin and according to the UK NICE guidelines should be offered to patients who have gastrointestinal tolerance issues with conventional metformin. We rechallenged patients with T2DM labelled as metformin-intolerant and treated with a DPP4i with a single-pill combination (SPC) of extended release metformin and sitagliptin (1000/50 mg) in...